Oric Pharmaceuticals (ORIC) Competitors $13.68 -0.40 (-2.84%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$13.56 -0.13 (-0.91%) As of 10/10/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORIC vs. KYMR, PTGX, CRNX, ZLAB, AKRO, ACAD, AAPG, MIRM, LNTH, and MENSShould you be buying Oric Pharmaceuticals stock or one of its competitors? The main competitors of Oric Pharmaceuticals include Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), Zai Lab (ZLAB), Akero Therapeutics (AKRO), ACADIA Pharmaceuticals (ACAD), Ascentage Pharma Group International (AAPG), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), and Jyong Biotech (MENS). These companies are all part of the "pharmaceutical products" industry. Oric Pharmaceuticals vs. Its Competitors Kymera Therapeutics Protagonist Therapeutics Crinetics Pharmaceuticals Zai Lab Akero Therapeutics ACADIA Pharmaceuticals Ascentage Pharma Group International Mirum Pharmaceuticals Lantheus Jyong Biotech Oric Pharmaceuticals (NASDAQ:ORIC) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation. Do analysts recommend ORIC or KYMR? Oric Pharmaceuticals currently has a consensus target price of $17.29, indicating a potential upside of 26.36%. Kymera Therapeutics has a consensus target price of $61.26, indicating a potential upside of 7.08%. Given Oric Pharmaceuticals' higher possible upside, analysts plainly believe Oric Pharmaceuticals is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oric Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70Kymera Therapeutics 1 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 2 Strong Buy rating(s) 2.95 Does the media favor ORIC or KYMR? In the previous week, Oric Pharmaceuticals had 6 more articles in the media than Kymera Therapeutics. MarketBeat recorded 11 mentions for Oric Pharmaceuticals and 5 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.87 beat Oric Pharmaceuticals' score of 0.43 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Kymera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ORIC or KYMR more profitable? Oric Pharmaceuticals has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -616.03%. Kymera Therapeutics' return on equity of -31.60% beat Oric Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Oric PharmaceuticalsN/A -51.75% -47.09% Kymera Therapeutics -616.03%-31.60%-27.12% Do insiders & institutionals believe in ORIC or KYMR? 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 6.8% of Oric Pharmaceuticals shares are owned by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, ORIC or KYMR? Oric Pharmaceuticals has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.26, suggesting that its share price is 126% more volatile than the S&P 500. Which has better valuation & earnings, ORIC or KYMR? Oric Pharmaceuticals has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOric PharmaceuticalsN/AN/A-$127.85M-$1.89-7.24Kymera Therapeutics$47.07M86.90-$223.86M-$3.47-16.49 SummaryKymera Therapeutics beats Oric Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Oric Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORIC vs. The Competition Export to ExcelMetricOric PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.37B$3.38B$6.10B$10.63BDividend YieldN/A2.29%5.67%4.71%P/E Ratio-7.2421.9785.2726.57Price / SalesN/A462.21612.78132.63Price / CashN/A47.2238.5062.09Price / Book3.9710.2112.726.53Net Income-$127.85M-$52.40M$3.30B$275.96M7 Day Performance18.34%0.88%0.94%-0.73%1 Month Performance25.97%10.41%6.34%3.71%1 Year Performance46.62%27.28%80.41%37.30% Oric Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORICOric Pharmaceuticals4.1525 of 5 stars$13.68-2.8%$17.29+26.4%+47.4%$1.37BN/A-7.2480News CoverageAnalyst ForecastInsider TradeKYMRKymera Therapeutics1.7801 of 5 stars$57.55-0.6%$61.26+6.5%+32.3%$4.14B$47.07M-16.58170Analyst ForecastPTGXProtagonist Therapeutics1.6659 of 5 stars$64.14-1.1%$68.36+6.6%+99.6%$4.03B$434.43M91.63120Trending NewsAnalyst ForecastCRNXCrinetics Pharmaceuticals3.779 of 5 stars$41.68+2.0%$74.45+78.6%-13.2%$3.85B$1.04M-10.14210Analyst ForecastZLABZai Lab2.7992 of 5 stars$33.31-1.3%$56.35+69.2%+19.4%$3.77B$398.99M-16.331,869News CoveragePositive NewsAnalyst ForecastAKROAkero Therapeutics3.702 of 5 stars$46.04-0.1%$81.14+76.2%+85.3%$3.69BN/A-23.0230Trending NewsAnalyst ForecastInsider TradeACADACADIA Pharmaceuticals4.4951 of 5 stars$21.59-1.0%$29.12+34.9%+37.9%$3.68B$1.02B16.23510Analyst RevisionAAPGAscentage Pharma Group InternationalN/A$39.86+1.2%N/AN/A$3.67B$134.35M0.00600News CoverageMIRMMirum Pharmaceuticals2.9902 of 5 stars$72.53-0.6%$76.50+5.5%+89.0%$3.66B$336.89M-59.94140News CoverageAnalyst ForecastLNTHLantheus4.5547 of 5 stars$52.70-2.1%$85.50+62.2%-50.5%$3.66B$1.53B14.02700Trending NewsAnalyst ForecastMENSJyong BiotechN/A$52.01+8.4%N/AN/A$3.65BN/A0.0031Analyst Forecast Related Companies and Tools Related Companies Kymera Therapeutics Competitors Protagonist Therapeutics Competitors Crinetics Pharmaceuticals Competitors Zai Lab Competitors Akero Therapeutics Competitors ACADIA Pharmaceuticals Competitors Ascentage Pharma Group International Competitors Mirum Pharmaceuticals Competitors Lantheus Competitors Jyong Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORIC) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oric Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oric Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
